GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL

NCT06875063 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Non-hodgkin Lymphoma
Refractory Lymphoma
Chimeric Antigen Receptor T-cell

Interventions

DRUG: GB5005 CART

Sponsor

The First Affiliated Hospital of Xiamen University